Abstract

P3.03-010 Identification of Mechanisms of Drug Resistance in RET-Rearranged Lung Cancer

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Cell Cycle Checkpoint Kinase and Drug Resistance of Lung Cancer
...
Chinese Journal of Lung Cancer | VOL. 24
, et. al. ...
20 Apr 2021
Role and potential therapeutic value of histone methyltransferases in drug resistance mechanisms in lung cancer.
Linxiang Zhang ... Xiaojing Wang
Frontiers in Oncology | VOL. 14
Linxiang Zhang, et. al.Linxiang Zhang ... Xiaojing Wang
08 Mar 2024
Abstract A139: Mechanism of treatment-induced drug resistance in lung cancer
Mark C Howell ... Shyam Mohapatra
Molecular Cancer Therapeutics | VOL. 17
Mark C Howell, et. al.Mark C Howell ... Shyam Mohapatra
01 Jan 2018
Analysis of the mechanisms of drug resistance in cancer by cDNA microarray
Khew-Voon Chin ... Manasi Ramanna
Nature genetics | VOL. 23
Khew-Voon Chin, et. al.Khew-Voon Chin ... Manasi Ramanna
01 Nov 1999
View more papers

More From: Journal of Thoracic Oncology

Paper Title
Journal
Date
Author
Real-world acute toxicity and 90-day mortality in patients with stage I non-small cell lung cancer treated with stereotactic body radiotherapy.
Peter S.N Van Rossum ... José S.A Belderbos
Journal of Thoracic Oncology | VOL. -
Peter S.N Van Rossum, et. al.Peter S.N Van Rossum ... José S.A Belderbos
25 Jul 2024
Analysis of Circulating Tumor DNA Predicts Outcomes of Short-Course Consolidation Immunotherapy in Unresectable Stage III NSCLC
Soyeong Jun ... Maximilian Diehn
Journal of Thoracic Oncology | VOL. -
Soyeong Jun, et. al.Soyeong Jun ... Maximilian Diehn
05 Jul 2024
PP01.133 Clinical and Economic Outcomes Associated with Genomic Testing Strategies in Real-World Data in Advanced Non-Small Cell Lung Cancer (aNSCLC)
Benjamin Levy ... Teddy Saliba
Journal of Thoracic Oncology | VOL. 19
Benjamin Levy, et. al.Benjamin Levy ... Teddy Saliba
01 Jul 2024
PP01.99 Switching to Subcutaneous (SC) Atezolizumab After Intravenous (IV) Dosing: Evaluation of Atezolizumab Pharmacokinetics (PK) Using Population PK Modeling
Stephanie N Liu ... Benjamin Wu
Journal of Thoracic Oncology | VOL. 19
Stephanie N Liu, et. al.Stephanie N Liu ... Benjamin Wu
01 Jul 2024
View more papers